Nan Fung Life Sciences

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
info
The average size of a deal this fund participated in
$61M
Portfolio companies 15
Rounds per year 5.00
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.40
Exits 6
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Life Science
  • Medical Device
Summary

The high activity for fund was in 2019. The higher amount of exits for fund were in 2019. The real fund results show that this VC is 10 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Nan Fung Life Sciences works on 19 percentage points less the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. Deals in the range of 50 - 100 millions dollars are the general things for fund.

Among the most popular portfolio startups of the fund, we may highlight Harmony Biosciences, Omniome, Bolt Biotherapeutics. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Nan Fung Life Sciences, startups are often financed by New Enterprise Associates, Novartis Venture Fund, Maveron. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, HBM Healthcare Investments AG, Vivo Capital. In the next rounds fund is usually obtained by Schwab Institutional, Pivotal bioVenture Partners China, Panacea Venture.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ACE Management France, Ile-de-France, Paris
Aitken Investments -
Bayview Capital Minnesota, United States, Wayzata
GFB ONLUS -
Loversoul -
Palomar Ventures California, Ladera Ranch, United States
The Futura Corp British Columbia, Canada, Vancouver
Wellington Management Boston, Massachusetts, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

DermBiont

Biotechnology
Health Care
Medical
Therapeutics
$28M21 Dec 2021 Boston, Massachusetts, United States

Ablaze Pharmaceuticals

Medical
Pharmaceutical
$75M29 Nov 2021 Jingan, Shanghai, China

Fountain Therapeutics

Biotechnology
Health Care
Therapeutics
$15M18 Nov 2021 San Francisco, California, United States

Engrail Therapeutics

Health Care
Life Science
Medical
Pharmaceutical
$32M03 Aug 2021 San Diego, California, United States

Oculis

Biotechnology
Health Care
Pharmaceutical
$57M04 May 2021 Iceland, Iceland

Arctic Vision

Biotechnology
Health Care
Life Science
$100M09 Mar 2021 Shanghai, China

Encodia

Biotechnology
Chemical
$75M27 Jan 2021 San Diego, California, United States

Eargo

Audio
Health Care
Medical Device
Wearables
$81M29 Jul 2020 San Jose, California, United States

Arctic Vision

Biotechnology
Health Care
Life Science
$32M13 Jul 2020 Shanghai, China
News
Engrail Therapeutics Extends Series A Financing to $64 Million

– Engrail Therapeutics announced the close of a $32m Series A extension round bringing total investment in the company to $64m.
– The round was led by Nan Fung Life Sciences following their leadership of the original Series A raise.
– The Company will use the proceeds to finance the advancement of its diverse pipeline, including lead assets ENX-101, ENX-102 and internal preclinical programs.
– Engrail’s lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles that possess wide ranging therapeutic utility.
– Engrail has assembled a diverse portfolio of assets with validated mechanisms through its dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Nan Fung Life Sciences?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: